Clinical Effect of Rosuvastatin Calcium Tablets on Patients with Primary Hypercholesterolemia

HE Bihong; SHI Dian

doi:10.14033/j.cnki.cfmr.2025.03.006

Abstract：Objective:To explore the therapeutic effect of rosuvastatin calcium tablets on patients with primary hypercholesterolemia.Method:109 patients with primary hypercholesterolemia admitted to the Third Hospital of Fuqing City from January 2022 to March 2024 were selected as the study objects,and were divided into control group(n=54)and study group(n=55)according to the odd-even method.The control group was treated with atorvastatin,while the study group was treated with rosuvastatin calcium tablets.The clinical efficacy and incidence of adverse reactions were compared between the two groups.The changes of blood lipid index,hypersensitive C-reactive protein,liver and kidney function were compared between the two groups.Result:The clinical effect of the study group was significantly better than that of the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the comparsion of adverse reactions between the study group and the control group(P＞0.05).After treatment,the levels of total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),apolipoprotein β and lipoprotein a in the study group were significantly lower than those in the control group,and the levels of high-density lipoprotein cholesterol(HDL-C)were significantly higher than those in the control group,with statistical significance(P＜0.05).The level of hypersensitive C-reactive protein in the study group was significantly lower than that in the control group after treatment,and the difference was statistically significant(P＜0.05).After treatment,alanine aminotransferase(ALT)and aspartate aminotransferase(AST)in the study group were lower than those in the control group,and the difference was statistically significant(P＜0.05).After treatment,serum creatinine(Scr)and blood urea nitrogen(BUN)in the study group were significantly lower than those in the control group,with statistical significance(P＜0.05).Conclusion:Rosuvastatin calcium tablets in the treatment of patients with primary hypercholesterolemia have definite clinical efficacy,which can improve blood lipid indexes,reduce the level of hypersensitive C-reactive protein,and reduce the influence on liver and kidney function.